Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEVARK)

Drug Name
GSK561679 Drug Info
Synonyms
VERUCERFONT; 885220-61-1; GSK561679; GSK561679A; UNII-X60608B091; GSK 561679A; NBI-77860; X60608B091; GSK561679;3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine; NBI 77860; Verucerfont [USAN:INN]; GSK 561679; GSK-561679; Verucerfont (USAN/INN); Verucerfont,GSK561679; SCHEMBL205309; CHEMBL1287935; EX-A1718; BDBM50417503; ZINC34661169; SB17107; CS-8099; DB12512; KB-77609; HY-14875; AC-30339; D09695
Indication
Disease Entry ICD 11 Status REF
Alcohol dependence 6C40.2 Phase 2 [1]
Major depressive disorder 6A70.3 Phase 2 [1]
Cross-matching ID
PubChem CID
11596613
CAS Number
CAS 885220-61-1
TTD Drug ID
DMEVARK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Corticotropin-releasing factor receptor 1 (CRHR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Telavancin DM58VQX Staphylococcus infection 1B5Y Approved [3]
Pexacerfont DMBJ15R Anxiety disorder 6B00-6B0Z Phase 2/3 [4]
SSR125543 DMGJEB8 Anxiety disorder 6B00-6B0Z Phase 2 [5]
ONO-2333Ms DMOT0WR Anxiety disorder 6B00-6B0Z Phase 2 [6]
Tildacerfont DMAB8LH Congenital adrenal hyperplasia 5A71.01 Phase 2 [7]
GSK586529 DM5E9LX Anxiety disorder 6B00-6B0Z Phase 1 [2]
GW876008 DMAXRBI Irritable bowel syndrome DD91.0 Discontinued in Phase 2 [4]
CP-316,311 DMZ76EM Major depressive disorder 6A70.3 Discontinued in Phase 2 [4]
CRA1000 DMWMBIV Anxiety disorder 6B00-6B0Z Preclinical [3]
NBI-37582 DM3JY2N Anxiety disorder 6B00-6B0Z Terminated [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Corticotropin-releasing factor receptor 1 (CRHR1) TT7EFHR CRFR1_HUMAN Antagonist [2]

References

1 ClinicalTrials.gov (NCT01187511) Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
3 A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
4 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
5 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6 Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86.
7 Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Nov 30;186(1):R1-R14.
8 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.